Adjuvant endocrine therapy for postmenopausal women with early stage breast cancer
نویسندگان
چکیده
†Author for correspondence 1Clinical Trial Coordinator, Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, The University of Birmingham, B15 2TT, UK Tel: +44 121 414 3797 Fax: +44 121 414 3700 [email protected] 2Senior Lecturer in Medical Oncology, Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, The University of Birmingham, B15 2TT, UK Tel: +44 121 414 5345 Fax: +44 121 414 3700 [email protected]
منابع مشابه
[Adjuvant chemotherapy of early stage breast cancer].
UNLABELLED Adjuvant systemic therapy reduces the likelihood of both local and distant relapses by eradicating micrometastases. AIM To survey the adjuvant treatment of early breast cancer. METHODS Author presents an overview of the systemic therapy of early breast cancer based on relevant literature and own experiences. RESULTS Three systemic treatment modalities are widely used as adjuvan...
متن کاملOptimizing Endocrine Therapy for Breast Cancer: 'Miles to Go'
The majority of invasive breast cancer patients present with hormone receptor-positive disease, and modulation of estrogen receptor (ER) activation is an essential component of systemic adjuvant therapy for these women. While tamoxifen has traditionally been the primary adjuvant endocrine therapy for all ER-positive women, recent trials evaluating the use of aromatase inhibitors (AIs) have chal...
متن کاملRecent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
BACKGROUND In the treatment of advanced breast cancer, third-generation aromatase inhibitors (AIs) have shown superior efficacy and tolerability compared with tamoxifen and megestrol acetate, the previous standard endocrine therapies in the first- and second-line settings, respectively. AIs are now being assessed in the adjuvant and prevention settings. DESIGN Literature review (PubMed search...
متن کاملReview Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention
Background: In the treatment of advanced breast cancer, third-generation aromatase inhibitors (AIs) have shown superior efficacy and tolerability compared with tamoxifen and megestrol acetate, the previous standard endocrine therapies in the firstand second-line settings, respectively. AIs are now being assessed in the adjuvant and prevention settings. Design: Literature review (PubMed search)....
متن کاملThe use of adjuvant bisphophonates in the treatment of early-stage breast cancer.
Adjuvant treatment of breast cancer has resulted in significant improvement in breast cancer-related outcomes. In addition to chemotherapy and endocrine therapy, the bone-protective agents known as bisphosphonates have been extensively investigated for their putative antitumor effect. Backed by strong preclinical data from in vitro and in vivo models, several randomized clinical trials have eva...
متن کاملAromatase inhibitors as adjuvant therapy in breast cancer.
The aromatase inhibitors are regarded as standard approaches to first- or second-line endocrine therapy in women with hormone-responsive metastatic breast cancer. Their efficacy and apparent lack of toxicity have led to their evaluation as adjuvant therapy. Although initial results with these agents in early breast cancer are promising, our collective long-term experience documenting tamoxifen'...
متن کامل